Caplin Point Laboratories Limited has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3rd and found compliant as per INVlMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,421 INR | +0.09% |
|
+2.93% | +4.76% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.76% | 129.21Cr | |
+16.50% | 4.21TCr | |
+20.78% | 2.17TCr | |
+21.14% | 1.57TCr | |
+23.69% | 1.49TCr | |
+57.44% | 1.31TCr | |
-0.05% | 678.76Cr | |
-14.94% | 629.94Cr | |
+20.03% | 605.07Cr | |
-8.87% | 572.55Cr |
- Stock Market
- Equities
- CAPLIPOINT Stock
- News Caplin Point Laboratories Limited
- Caplin Point Laboratories Limited Receives Colombia's INVIMA Approval for Its Softgel Capsules Division At Puducherry